Nosocomial infection rates of three-years in neurological intensive care unit and relationship to mortality


Creative Commons License

Bilge N., Yevgi R., Ceylan M., Parlak E., Şimşek F.

Anatolian Current Medical Journal, cilt.3, sa.2, ss.158-164, 2021 (Hakemli Dergi)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 3 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.38053/acmj.885326
  • Dergi Adı: Anatolian Current Medical Journal
  • Derginin Tarandığı İndeksler: Index Copernicus
  • Sayfa Sayıları: ss.158-164
  • Atatürk Üniversitesi Adresli: Evet

Özet

ABSTRACT Aim: The risk of developing nosocomial infections (NI) is higher in intensive care units (ICU). Recognition and treatment of NI is important in reducing mortality and morbidity. The aim of this study was to investigate the clinical and demographic characteristics, rates of mortality and nosocomial infection, agents of infection and antibiotic resistance rates of patients the neurological ICU. Material and Method: The study was carried out between the dates of 01/06/2015 and 01/06/2018 in Neurological ICU. Data of all patients aged were retrospectively analyzed in accordance with the National Nosocomial Infections Surveillance System. SPSS 23 software was used for statistical analysis. Results: Throughout the 3-year period, a total of 641 patients were followed up in the Neurological ICU and the most common diagnosis was ischemic cerebrovascular disease. It was found that 641 NIs developed in 55 patients in 5334 days of hospitalization in three years and the mortality rate was significantly higher in those with a NI (83.6%) compared to patients without a NI. The rate of NI the mean rate in three years was 9.98% and the most common NI was device-associated infections. In the 3-year period, the most common pathogen was A.bauamannii which was susceptible to colistin in 100% of the cases, and resistant to imipenem in 96% of the cases. Conclusions: The use of invasive tools should be reduced in order to reduce nosocomial infection and mortality rates in the ICU. Each ICU should monitor its own nosocomial infection agents and resistance rates and develop a rational antibiotic use.